{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:52:58Z","timestamp":1740163978562,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009420","name":"Varsinais-Suomen Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009420","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005609","name":"Turun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["322123","296801","310561","314443","329278","335434","335611","341342"],"award-info":[{"award-number":["322123","296801","310561","314443","329278","335434","335611","341342"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["677943"],"award-info":[{"award-number":["677943"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["955321"],"award-info":[{"award-number":["955321"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022768","name":"Maire Lisko Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022768","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Frequent laboratory monitoring is recommended for early identification of toxicity when initiating conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). We aimed at developing a risk prediction model to individualize laboratory testing at csDMARD initiation. We identified inflammatory joint disease patients (N\u2009=\u20091196) initiating a csDMARD in Turku University Hospital 2013\u20132019. Baseline and follow-up safety monitoring results were drawn from electronic health records. For rheumatoid arthritis patients, diagnoses and csDMARD initiation\/cessation dates were manually confirmed. Primary endpoint was alanine transaminase (ALT) elevation of more than twice the upper limit of normal (ULN) within 6\u00a0months after treatment initiation. Computational models for predicting incident ALT elevations were developed using Lasso Cox proportional hazards regression with stable iterative variable selection (SIVS) and were internally validated against a randomly selected test cohort (1\/3 of the data) that was not used for training the models. Primary endpoint was reached in 82 patients (6.9%). Among baseline variables, Lasso model with SIVS predicted subsequent ALT elevations of &gt;\u20092\u2009\u00d7\u2009ULN using higher ALT, csDMARD other than methotrexate or sulfasalazine and psoriatic arthritis diagnosis as important predictors, with a\u00a0concordance index of 0.71 in the test cohort. Respectively, at first follow-up, in addition to baseline ALT and psoriatic arthritis diagnosis, also ALT change from baseline was identified as an important predictor resulting in a test concordance index of 0.72. Our computational model predicts ALT elevations after the first follow-up test with good accuracy and can help in optimizing individual testing frequency.<\/jats:p>","DOI":"10.1038\/s41598-023-39694-2","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:02:40Z","timestamp":1691596960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of prediction model for alanine transaminase elevations during the first 6\u00a0months of conventional synthetic DMARD treatment"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-8439","authenticated-orcid":false,"given":"Laura","family":"Kuusalo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko S.","family":"Ven\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Kirjala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Saranp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Elo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Piril\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"39694_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res. 59, 762\u2013784. https:\/\/doi.org\/10.1002\/art.23721 (2008).","journal-title":"Arthritis Care Res."},{"key":"39694_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser, K. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68, 1086\u20131093. https:\/\/doi.org\/10.1136\/ard.2008.094474 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"39694_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64, 625\u2013639. https:\/\/doi.org\/10.1002\/acr.21641 (2012).","journal-title":"Arthritis Care Res."},{"key":"39694_CR4","first-page":"249","volume":"74","author":"K Taimen","year":"2019","unstructured":"Taimen, K., Eklund, K., Kaipiainen-Sepp\u00e4nen, O., Karjalainen, A. & M\u00e4kinen, H. Reumal\u00e4\u00e4kityksen laboratorioseuranta\u2014Ohjeet p\u00e4ivitetty. Finn. Med. J. 74, 249\u2013251 (2019).","journal-title":"Finn. Med. J."},{"key":"39694_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","volume":"56","author":"J Ledingham","year":"2017","unstructured":"Ledingham, J. et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 56, 865\u2013868. https:\/\/doi.org\/10.1093\/rheumatology\/kew479 (2017).","journal-title":"Rheumatology (Oxford)"},{"key":"39694_CR6","doi-asserted-by":"publisher","first-page":"e0194401","DOI":"10.1371\/journal.pone.0194401","volume":"13","author":"FTM Busger op Vollenbroek","year":"2018","unstructured":"Busger op Vollenbroek, F. T. M., Doggen, C. J. M., Janssens, R. W. A. & Bernelot Moens, H. J. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE 13, e0194401. https:\/\/doi.org\/10.1371\/journal.pone.0194401 (2018).","journal-title":"PLoS ONE"},{"key":"39694_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/acr.22294","volume":"66","author":"G Schmajuk","year":"2014","unstructured":"Schmajuk, G. et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 66, 1159\u20131166. https:\/\/doi.org\/10.1002\/acr.22294 (2014).","journal-title":"Arthritis Care Res."},{"key":"39694_CR8","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/rheumatology\/kez168","volume":"58","author":"T Malley","year":"2019","unstructured":"Malley, T., Corfield, G., Fung, P., Heneghan, D. & Kitchen, J. Transaminitis and neutropenia are rare in patients on methotrexate: Evidence from a large cohort of inflammatory arthritis patients. Rheumatology (Oxford) 58, 2061\u20132062. https:\/\/doi.org\/10.1093\/rheumatology\/kez168 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"39694_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/1756-185X.13576","volume":"22","author":"J Karlsson Sundbaum","year":"2019","unstructured":"Karlsson Sundbaum, J. et al. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. Int. J. Rheum. Dis. 22, 1226\u20131232. https:\/\/doi.org\/10.1111\/1756-185X.13576 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"39694_CR10","first-page":"1727","volume":"31","author":"PD Kent","year":"2004","unstructured":"Kent, P. D., Luthra, H. S. & Michet, C. Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J. Rheumatol. 31, 1727\u20131731 (2004).","journal-title":"J. Rheumatol."},{"key":"39694_CR11","doi-asserted-by":"publisher","first-page":"rkaa020","DOI":"10.1093\/rap\/rkaa020","volume":"4","author":"S Mori","year":"2020","unstructured":"Mori, S. et al. Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: A longitudinal cohort study. Rheumatol. Adv. Pract. 4, rkaa020. https:\/\/doi.org\/10.1093\/rap\/rkaa020 (2020).","journal-title":"Rheumatol. Adv. Pract."},{"key":"39694_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10067-012-2136-8","volume":"32","author":"L Dirven","year":"2013","unstructured":"Dirven, L. et al. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin. Rheumatol. 32, 585\u2013590. https:\/\/doi.org\/10.1007\/s10067-012-2136-8 (2013).","journal-title":"Clin. Rheumatol."},{"key":"39694_CR13","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1093\/bioinformatics\/btab501","volume":"37","author":"M Mahmoudian","year":"2021","unstructured":"Mahmoudian, M., Ven\u00e4l\u00e4inen, M. S., Kl\u00e9n, R. & Elo, L. L. Stable iterative variable selection. Bioinformatics 37, 4810\u20134817. https:\/\/doi.org\/10.1093\/bioinformatics\/btab501 (2021).","journal-title":"Bioinformatics"},{"key":"39694_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/HJH.0000000000002282","volume":"38","author":"MS Ven\u00e4l\u00e4inen","year":"2020","unstructured":"Ven\u00e4l\u00e4inen, M. S., Kl\u00e9n, R., Mahmoudian, M., Raitakari, O. T. & Elo, L. L. Easy-to-use tool for evaluating the elevated acute kidney injury risk against reduced cardiovascular disease risk during intensive blood pressure control. J. Hypertens. 38, 511\u2013518. https:\/\/doi.org\/10.1097\/HJH.0000000000002282 (2020).","journal-title":"J. Hypertens."},{"key":"39694_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/cam4.4465","volume":"11","author":"MS Ven\u00e4l\u00e4inen","year":"2022","unstructured":"Ven\u00e4l\u00e4inen, M. S. et al. Improved risk prediction of chemotherapy-induced neutropenia-model development and validation with real-world data. Cancer Med. 11, 654\u2013663. https:\/\/doi.org\/10.1002\/cam4.4465 (2022).","journal-title":"Cancer Med."},{"key":"39694_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"T Therneau","year":"2000","unstructured":"Therneau, T. & Grambsch, P. Modeling Survival Data: Extending the Cox Model (Springer, 2000)."},{"key":"39694_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2009","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2009)."},{"key":"39694_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"39694_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/anr.1780320202","volume":"32","author":"JM Kremer","year":"1989","unstructured":"Kremer, J. M., Lee, R. G. & Tolman, K. G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 32, 121\u2013127. https:\/\/doi.org\/10.1002\/anr.1780320202 (1989).","journal-title":"Arthritis Rheum."},{"key":"39694_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen, P. & Skov, L. Psoriasis and obesity. Dermatology 232, 633\u2013639. https:\/\/doi.org\/10.1159\/000455840 (2016).","journal-title":"Dermatology"},{"key":"39694_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","volume":"71","author":"W Li","year":"2012","unstructured":"Li, W., Han, J. & Qureshi, A. A. Obesity and risk of incident psoriatic arthritis in US women. Ann. Rheum. Dis. 71, 1267\u20131272. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201273 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"39694_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3899\/jrheum.181312","volume":"47","author":"R Pakchotanon","year":"2020","unstructured":"Pakchotanon, R., Ye, J. Y., Cook, R. J., Chandran, V. & Gladman, D. D. Liver abnormalities in patients with psoriatic arthritis. J. Rheumatol. 47, 847\u2013853. https:\/\/doi.org\/10.3899\/jrheum.181312 (2020).","journal-title":"J. Rheumatol."},{"key":"39694_CR23","doi-asserted-by":"publisher","first-page":"152165","DOI":"10.1016\/j.semarthrit.2023.152165","volume":"59","author":"K Torosian","year":"2023","unstructured":"Torosian, K. et al. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin. Arthritis Rheum. 59, 152165. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152165 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"39694_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semarthrit.2015.05.003","volume":"45","author":"R Conway","year":"2015","unstructured":"Conway, R., Low, C., Coughlan, R. J., O\u2019Donnell, M. J. & Carey, J. J. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. Semin. Arthritis Rheum. 45, 156\u2013162. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.003 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"39694_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon, D. H. et al. Adverse effects of low-dose methotrexate: A randomized trial. Ann. Intern. Med. 172, 369\u2013380. https:\/\/doi.org\/10.7326\/M19-3369 (2020).","journal-title":"Ann. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39694-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:06:23Z","timestamp":1700409983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39694-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39694"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39694-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12943"}}